{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:46:13Z","timestamp":1795034773609,"version":"4.10.2"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01719-5","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:04:35Z","timestamp":1743033875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform"],"prefix":"10.1186","volume":"17","author":[{"given":"Francisco","family":"Mart\u00ednez-Dubarbie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Guerra-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"L\u00f3pez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fern\u00e1ndez-Matarrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Nevado-C\u00e1ceres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rivera-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Valera-Barrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pozueta-Cantudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Corrales-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"L\u00f3pez-Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Irure-Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Marco","family":"de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Drake-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Heidy","family":"Cahuana-Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Garc\u00eda-Unzueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascual","family":"S\u00e1nchez-Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloy","family":"Rodr\u00edguez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"4","key":"1719_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1719_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"1","key":"1719_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"1719_CR4","unstructured":"US Food and Drug Administration. Drugs@ FDA: FDA... - Google Acad\u00e9mico. https:\/\/scholar.google.com\/scholar_lookup?journal=Drugs@FDA:+FDA-Approved+Drugs+-+Aducanumab&publication_year=2021&. Accessed 28 Aug 2024."},{"issue":"1","key":"1719_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/ADR-230029","volume":"7","author":"MV Pais","year":"2023","unstructured":"Pais MV, Forlenza OV, Diniz BS. Plasma biomarkers of Alzheimer\u2019s disease: a review of available assays, recent developments, and implications for clinical practice. J Alzheimers Dis Rep. 2023;7(1):355\u201380. https:\/\/doi.org\/10.3233\/ADR-230029. Published 2023 May 3.","journal-title":"J Alzheimers Dis Rep."},{"issue":"5","key":"1719_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1719_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141(5):709\u201324. https:\/\/doi.org\/10.1007\/s00401-021-02275-6.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"1719_CR8","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w.","journal-title":"Nat Med"},{"issue":"11","key":"1719_CR9","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144(11):3505\u201316. https:\/\/doi.org\/10.1093\/brain\/awab223.","journal-title":"Brain"},{"key":"1719_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand AL, Lawler PE, Bollinger JG, et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimers Res Ther. 2022;14:195. https:\/\/doi.org\/10.1186\/s13195-022-01117-1.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"1719_CR11","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1093\/brain\/awaa329","volume":"143","author":"CE Teunissen","year":"2020","unstructured":"Teunissen CE, Thijssen EH, Verberk IMW. Plasma p-tau217: from \u201cnew kid\u201d to most promising candidate for Alzheimer\u2019s disease blood test. Brain. 2020;143(11):3170\u20132. https:\/\/doi.org\/10.1093\/brain\/awaa329.","journal-title":"Brain"},{"issue":"1","key":"1719_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-022-01005-8","volume":"14","author":"C Groot","year":"2022","unstructured":"Groot C, Cicognola C, Bali D, et al. Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimers Res Ther. 2022;14(1):67. https:\/\/doi.org\/10.1186\/s13195-022-01005-8.","journal-title":"Alzheimers Res Ther"},{"issue":"22","key":"1719_CR13","doi-asserted-by":"publisher","first-page":"e3026","DOI":"10.1212\/WNL.0000000000010814","volume":"95","author":"J Hanes","year":"2020","unstructured":"Hanes J, Kovac A, Kvartsberg H, et al. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology. 2020;95(22):e3026\u201335. https:\/\/doi.org\/10.1212\/WNL.0000000000010814.","journal-title":"Neurology"},{"issue":"8","key":"1719_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","journal-title":"JAMA"},{"issue":"2","key":"1719_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00415-025-12897-5","volume":"272","author":"J Sarto","year":"2025","unstructured":"Sarto J, Esteller-Gauxax D, Guill\u00e9n N, et al. Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer\u2019s disease diagnosis in a memory clinic cohort. J Neurol. 2025;272(2):160. https:\/\/doi.org\/10.1007\/s00415-025-12897-5. Published 2025 Jan 23.","journal-title":"J Neurol"},{"issue":"10","key":"1719_CR16","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1002\/alz.13393","volume":"19","author":"PCL Ferreira","year":"2023","unstructured":"Ferreira PCL, Therriault J, Tissot C, et al. Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimers Dement. 2023;19(10):4463\u201374. https:\/\/doi.org\/10.1002\/alz.13393.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1719_CR17","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3 G, Ossenkoppele R, Ashton NJ, et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med. 2023;15(5): e17123. https:\/\/doi.org\/10.15252\/emmm.202217123.","journal-title":"EMBO Mol Med"},{"key":"1719_CR18","doi-asserted-by":"publisher","unstructured":"Zhong X, Wang Q, Yang M, et al. Plasma p-tau217 and p-tau217\/A\u03b21\u201342 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer's disease: Insights for research and clinical practice. Alzheimers Dement. 2025. https:\/\/doi.org\/10.1002\/alz.14536.","DOI":"10.1002\/alz.14536"},{"issue":"4","key":"1719_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 2023;80(4):360\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5272.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1719_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1719_CR21","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain. 2020;143(11):3234\u201341. https:\/\/doi.org\/10.1093\/brain\/awaa286.","journal-title":"Brain"},{"issue":"3","key":"1719_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/alz.12706","volume":"19","author":"NC Cullen","year":"2023","unstructured":"Cullen NC, Janelidze S, Mattsson-Carlgren N, et al. Test-retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models. Alzheimers Dement. 2023;19(3):797\u2013806. https:\/\/doi.org\/10.1002\/alz.12706.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1719_CR23","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","volume":"271","author":"AJ Mendes","year":"2024","unstructured":"Mendes AJ, Ribaldi F, Lathuiliere A, et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol. 2024;271(4):2053\u201366. https:\/\/doi.org\/10.1007\/s00415-023-12148-5.","journal-title":"J Neurol"},{"issue":"4","key":"1719_CR24","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146(4):1592\u2013601. https:\/\/doi.org\/10.1093\/brain\/awac333.","journal-title":"Brain"},{"issue":"6","key":"1719_CR25","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.14283\/jpad.2024.152","volume":"11","author":"F Mart\u00ednez-Dubarbie","year":"2024","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, et al. Diagnostic accuracy of plasma p-tau217 for detecting pathological cerebrospinal fluid changes in cognitively unimpaired subjects using the lumipulse platform. J Prev Alzheimers Dis. 2024;11(6):1581\u201391. https:\/\/doi.org\/10.14283\/jpad.2024.152.","journal-title":"J Prev Alzheimers Dis"},{"key":"1719_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae368","author":"A Pilotto","year":"2024","unstructured":"Pilotto A, Quaresima V, Trasciatti C, et al. Plasma p-tau217 in Alzheimer\u2019s disease: Lumipulse and ALZpath SIMOA head-to-head comparison. Brain. 2024. https:\/\/doi.org\/10.1093\/brain\/awae368.","journal-title":"Brain"},{"key":"1719_CR27","doi-asserted-by":"publisher","unstructured":"Schindler SE, Petersen KK, Saef B, et al. Head-to-head comparison of leading blood tests for Alzheimer's disease pathology [published correction appears in Alzheimers Dement. 2024 Dec 30. 10.1002\/alz.14494]. Alzheimers Dement. 2024;20(11):8074\u20138096. https:\/\/doi.org\/10.1002\/alz.14315.","DOI":"10.1002\/alz.14315"},{"key":"1719_CR28","doi-asserted-by":"publisher","DOI":"10.12703\/r\/10-46","volume":"10","author":"S Narayanan","year":"2021","unstructured":"Narayanan S, Shanker A, Khera T, Subramaniam B. Neurofilament light: a narrative review on biomarker utility. Fac Rev. 2021;10: 46. https:\/\/doi.org\/10.12703\/r\/10-46.","journal-title":"Fac Rev"},{"issue":"5","key":"1719_CR29","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000011226","volume":"96","author":"I Ill\u00e1n-Gala","year":"2021","unstructured":"Ill\u00e1n-Gala I, Lleo A, Karydas A, et al. Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology. 2021;96(5):e671\u201383. https:\/\/doi.org\/10.1212\/WNL.0000000000011226.","journal-title":"Neurology"},{"issue":"5","key":"1719_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer\u2019s disease neuroimaging initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6117.","journal-title":"JAMA Neurol"},{"issue":"7","key":"1719_CR31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the global CEO initiative on Alzheimer\u2019s disease. Nat Rev Neurol. 2024;20(7):426\u201339. https:\/\/doi.org\/10.1038\/s41582-024-00977-5.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"1719_CR32","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen JA, Campbell MR, Algeciras-Schimnich A, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18(6):1128\u201340. https:\/\/doi.org\/10.1002\/alz.12466.","journal-title":"Alzheimers Dement"},{"key":"1719_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14430","author":"M Olvera-Rojas","year":"2024","unstructured":"Olvera-Rojas M, Sewell KR, Karikari TK, et al. Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217\/A\u03b242. Alzheimers Dement. 2024. https:\/\/doi.org\/10.1002\/alz.14430.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"1719_CR34","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community [published correction appears in Nat Med. 2023 Nov;29(11):2954. 10.1038\/s41591-022-02066-w.]. Nat Med. 2022;28(7):1398\u2013405. https:\/\/doi.org\/10.1038\/s41591-022-01822-2.","journal-title":"Nat Med"},{"issue":"1","key":"1719_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13195-023-01319-1","volume":"15","author":"F Mart\u00ednez-Dubarbie","year":"2023","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, et al. Accuracy of plasma A\u03b240, A\u03b242, and p-tau181 to detect CSF Alzheimer\u2019s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform. Alzheimers Res Ther. 2023;15(1):163. https:\/\/doi.org\/10.1186\/s13195-023-01319-1.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1719_CR36","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-022-01116-2","volume":"14","author":"EN Wilson","year":"2022","unstructured":"Wilson EN, Young CB, Ramos Benitez J, et al. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):172. https:\/\/doi.org\/10.1186\/s13195-022-01116-2.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1719_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther. 2024;16(1):139. https:\/\/doi.org\/10.1186\/s13195-024-01513-9.","journal-title":"Alzheimers Res Ther"},{"key":"1719_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.663446","volume":"13","author":"S L\u00f3pez-Garc\u00eda","year":"2021","unstructured":"L\u00f3pez-Garc\u00eda S, Lage C, Pozueta A, et al. Sleep time estimated by an actigraphy watch correlates with CSF tau in cognitively unimpaired elders: the modulatory role of APOE. Front Aging Neurosci. 2021;13: 663446. https:\/\/doi.org\/10.3389\/fnagi.2021.663446.","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"1719_CR39","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a.","journal-title":"Neurology"},{"issue":"4\u20135","key":"1719_CR40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clinbiochem.2013.12.024","volume":"47","author":"CE Teunissen","year":"2014","unstructured":"Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem. 2014;47(4\u20135):288\u201392. https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.12.024.","journal-title":"Clin Biochem"},{"issue":"4","key":"1719_CR41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Andreasson U, Persson S, et al. The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7(4):386-395.e6. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2243.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1719_CR42","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484\u201397. https:\/\/doi.org\/10.1002\/alz.12510.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1719_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom J, Parnetti L, Rosa-Neto P, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med. 2022;60(2):207\u201319. https:\/\/doi.org\/10.1515\/cclm-2021-0651.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"1719_CR44","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archneurol.2010.179","volume":"67","author":"G De Meyer","year":"2010","unstructured":"De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67(8):949\u201356. https:\/\/doi.org\/10.1001\/archneurol.2010.179.","journal-title":"Arch Neurol"},{"issue":"5","key":"1719_CR45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347. https:\/\/doi.org\/10.1212\/WNL.0000000000002923.","journal-title":"Neurology"},{"issue":"3","key":"1719_CR46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res."},{"issue":"4","key":"1719_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/arclin\/acp027","volume":"24","author":"J Pe\u00f1a-Casanova","year":"2009","unstructured":"Pe\u00f1a-Casanova J, Blesa R, Aguilar M, et al. Spanish multicenter normative studies (NEURONORMA project): methods and sample characteristics. Arch Clin Neuropsychol. 2009;24(4):307\u201319. https:\/\/doi.org\/10.1093\/arclin\/acp027.","journal-title":"Arch Clin Neuropsychol"},{"issue":"9","key":"1719_CR48","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","volume":"139","author":"B Reisberg","year":"1982","unstructured":"Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136\u20139. https:\/\/doi.org\/10.1176\/ajp.139.9.1136.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1719_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89(1):88\u2013100. https:\/\/doi.org\/10.1212\/WNL.0000000000004058.","journal-title":"Neurology"},{"issue":"2","key":"1719_CR50","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2017.01.008","volume":"35","author":"NT Olney","year":"2017","unstructured":"Olney NT, Spina S, Miller BL. Frontotemporal Dementia. Neurol Clin. 2017;35(2):339\u201374. https:\/\/doi.org\/10.1016\/j.ncl.2017.01.008.","journal-title":"Neurol Clin"},{"issue":"3","key":"1719_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1719_CR52","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jalz.2016.10.007","volume":"13","author":"OA Skrobot","year":"2017","unstructured":"Skrobot OA, O\u2019Brien J, Black S, et al. The vascular impairment of cognition classification consensus study. Alzheimers Dement. 2017;13(6):624\u201333. https:\/\/doi.org\/10.1016\/j.jalz.2016.10.007.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1719_CR53","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/archneur.1996.00550090125018","volume":"53","author":"HA Kretzschmar","year":"1996","unstructured":"Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol. 1996;53(9):913\u201320. https:\/\/doi.org\/10.1001\/archneur.1996.00550090125018.","journal-title":"Arch Neurol"},{"issue":"9","key":"1719_CR54","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1719_CR55","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3390\/ijms25031481","volume":"25","author":"F Mart\u00ednez-Dubarbie","year":"2024","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, et al. Influence of physiological variables and comorbidities on plasma A\u03b240, A\u03b242, and p-tau181 levels in cognitively unimpaired individuals. Int J Mol Sci. 2024;25(3):1481. https:\/\/doi.org\/10.3390\/ijms25031481. Published 2024 Jan 25.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1719_CR56","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging. 2023;3(9):1079\u201390. https:\/\/doi.org\/10.1038\/s43587-023-00471-5.","journal-title":"Nat Aging"},{"issue":"12","key":"1719_CR57","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386. https:\/\/doi.org\/10.1002\/alz.12756.","journal-title":"Alzheimers Dement"},{"issue":"15","key":"1719_CR58","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA. 2024;332(15):1245\u201357. https:\/\/doi.org\/10.1001\/jama.2024.13855.","journal-title":"JAMA"},{"issue":"8","key":"1719_CR59","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"1719_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115522","volume":"211","author":"AR Monteiro","year":"2023","unstructured":"Monteiro AR, Barbosa DJ, Remi\u00e3o F, Silva R. Alzheimer\u2019s disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol. 2023;211: 115522. https:\/\/doi.org\/10.1016\/j.bcp.2023.115522.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"1719_CR61","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00214-3.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1719_CR62","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/brain\/awab099","volume":"144","author":"S Spina","year":"2021","unstructured":"Spina S, La Joie R, Petersen C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain. 2021;144(7):2186\u201398. https:\/\/doi.org\/10.1093\/brain\/awab099.","journal-title":"Brain"},{"issue":"6","key":"1719_CR63","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","volume":"90","author":"\u00c5 Sandelius","year":"2018","unstructured":"Sandelius \u00c5, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90(6):e518\u201324. https:\/\/doi.org\/10.1212\/WNL.0000000000004932.","journal-title":"Neurology"},{"issue":"1","key":"1719_CR64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13195-024-01555-z","volume":"16","author":"AH Dyer","year":"2024","unstructured":"Dyer AH, Dolphin H, O\u2019Connor A, et al. Performance of plasma p-tau217 for the detection of amyloid-\u03b2 positivity in a memory clinic cohort using an electrochemiluminescence immunoassay. Alzheimers Res Ther. 2024;16(1):186. https:\/\/doi.org\/10.1186\/s13195-024-01555-z.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1719_CR65","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barth\u00e9lemy","year":"2023","unstructured":"Barth\u00e9lemy NR, Saef B, Li Y, et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat Aging. 2023;3(4):391\u2013401. https:\/\/doi.org\/10.1038\/s43587-023-00380-7.","journal-title":"Nat Aging"},{"issue":"4","key":"1719_CR66","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19(4):1403\u201314. https:\/\/doi.org\/10.1002\/alz.12787.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1719_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13195-024-01391-1","volume":"16","author":"D Bali","year":"2024","unstructured":"Bali D, Hansson O, Janelidze S. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217. Alzheimers Res Ther. 2024;16(1):31. https:\/\/doi.org\/10.1186\/s13195-024-01391-1.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1719_CR68","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1515\/cclm-2022-0770","volume":"61","author":"G Musso","year":"2023","unstructured":"Musso G, Cosma C, Zaninotto M, Gabelli C, Basso D, Plebani M. Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer\u2019s disease. Clin Chem Lab Med. 2023;61(3):e53\u20136. https:\/\/doi.org\/10.1515\/cclm-2022-0770.","journal-title":"Clin Chem Lab Med"},{"key":"1719_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100056","author":"M Sch\u00f6ll","year":"2025","unstructured":"Sch\u00f6ll M, Vrillon A, Ikeuchi T, et al. Cutting through the noise: a narrative review of Alzheimer\u2019s disease plasma biomarkers for routine clinical use. J Prev Alzheimers Dis. 2025. https:\/\/doi.org\/10.1016\/j.tjpad.2024.100056.","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"1719_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011146","volume":"7","author":"L Lang","year":"2017","unstructured":"Lang L, Clifford A, Wei L, et al. Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis. BMJ Open. 2017;7(2): e011146. https:\/\/doi.org\/10.1136\/bmjopen-2016-011146. Published 2017 Feb 3.","journal-title":"BMJ Open."},{"issue":"12","key":"1719_CR71","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, et al. Alzheimer disease as a clinical-biological construct-an International Working Group recommendation. JAMA Neurol. 2024;81(12):1304\u201311. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3770.","journal-title":"JAMA Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01719-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:04:40Z","timestamp":1743033880000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01719-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1719"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01719-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research has been conducted in accordance with the Declaration of Helsinki and has been approved by the ethics committee of the Hospital Universitario Marqu\u00e9s de Valdecilla. Title: Valdecilla Cohort for the study of memory and brain aging. Internal code: 2018.111.All subjects have given their signed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}